News for Healthier Living
SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.
September 1, 2024
September 17 2024September 16 2024September 15 2024September 14 2024September 13 2024September 12 2024September 11 2024September 10 2024September 9 2024September 8 2024September 7 2024September 6 2024September 5 2024September 4 2024September 3 2024
|
|
|
|
|